Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Prolia® (denosumab) – New indication
May 21, 2018 - Amgen announced the FDA approval of Prolia (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk for fracture.
